White Paper
Testing the CAR Risk mitigation in autologous CAR-T therapy clinical trials in oncology
Jan 13, 2023
Activity in the field of Cell and Gene Therapy (CAGT) has been steadily increasing as the techniques are refined, and patient selection and monitoring are standardized. This white paper builds on the first paper in the CAGT Hot Buttons series, “Introduction to Autologous CAR-T therapy”. Here, we discuss frequently encountered medical hazards of the most widely available autologous Chimeric Antigen Receptor T-cell (CAR-T) therapies in the B cell hematologic malignancy patient population.
WHITE PAPER
Starting the CAR An Introduction To Autologous CAR-T Therapy
The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field. In this whitepaper, we summarize the CAR-T regulatory status from Asia-Pacific markets, basics of CAR-T receptor structure and look at the common toxicities of currently available CAR-T therapies which have regulatory approval for hematological malignancies.